[1] BROOKS RA, FLEMING GF, LASTRA RR, et al. Current recommendations and recent progress in endometrial cancer[J]. CA Cancer J Clin, 2019, 69(4): 258-279.
[2] ONSTAD MA, SCHMANDT RE, LU KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment[J]. J Clin Oncol, 2016, 34(35): 4225-4230.
[3] SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1): 7-30.
[4] DOHERTY MT, SANNI OB, COLEMAN HG, et al. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: a systematic review and meta-analysis[J]. PLoS One, 2020, 15(4): e0232231.
[5] FAN Z, LI H, HU R, et al. Fertility-preserving treatment in young women with grade 1 presumed stage IA endometrial adenocarcinoma: a meta-analysis[J]. Int J Gynecol Cancer, 2018, 28(2): 385-393.
[6] WEI J, ZHANG W, FENG L, et al. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: a meta-analysis and systematic review[J]. Medicine (Baltimore), 2017, 96(37): e8034.
[7] DIEPLINGER H, ANKERST DP, BURGES A, et al. Afamin and apolipoprotein A-Ⅳ: novel protein markers for ovarian cancer[J]. Cancer Epidemiol Biomarkers Prev, 2009, 18(4): 1127-1133.
[8] ZHANG X, ZHAO XW, LIU DB, et al. Lipid levels in serum and cancerous tissues of colorectal cancer patients[J]. World J Gastroenterol, 2014, 20(26): 8646-8652.
[9] CHEN H, CHU LY, LI XH, et al. ApoB/ApoA-1 ratio as a novel prognostic predictor in patients with primary small cell carcinoma of the esophagus[J]. Front Oncol, 2020, 10: 610.
[10] YANG DD, CHEN ZH, WANG DS, et al. Prognostic value of the serum apolipoprotein B to apolipoprotein a-I ratio in metastatic colorectal cancer patients[J]. J Cancer, 2020, 11(5): 1063-1074.
[11] FARIAS-EISNER G, SU F, ROBBINS T, et al. Validation of serum biomarkers for detection of early- and late-stage endometrial cancer[J]. Am J Obstet Gynecol, 2010, 202(1): 73. e1-e5.
[12] SU F, KOZAK KR, IMAIZUMI S, et al. Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer[J]. Proc Natl Acad Sci U S A, 2010, 107(46): 19997-20002.
[13] GAO F, VASQUEZ SX, SU F, et al. L-5f, an apolipoprotein A-I mimetic, inhibits tumor angiogenesis by suppressing VEGF/basic FGF signaling pathways[J]. Integr Biol (Camb), 2011, 3(4): 479-489.
[14] GANAPATHY E, SU F, MERIWETHER D, et al. D-4f, an Apoa-I mimetic peptide, inhibits proliferation and tumorigenicity of epithelial ovarian cancer cells by upregulating the antioxidant enzyme MnSOD[J]. Int J Cancer, 2012, 130(5): 1071-1081.
[15] TURCO MY, GARDNER L, HUGHES J, et al. Long-term, hormone-responsive organoid cultures of human endometrium in a chemically defined medium[J]. Nat Cell Biol, 2017, 19(5): 568-577.
[16] GIANNONE G, ATTADEMO L, SCOTTO G, et al. Endometrial cancer stem cells: role, characterization and therapeutic implications[J]. Cancers (Basel), 2019, 11(11): 1820.
[17] WANG X, JIN J, WAN F, et al. Ampk promotes spop-mediated nanog degradation to regulate prostate cancer cell stemness[J]. Dev Cell, 2019, 48(3): 345-360. e7.
[18] ZHANG Z, JR. BAST RC, YU Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer[J]. Cancer Res, 2004, 64(16): 5882-5890.
[19] PIETROWSKA M, JELONEK K, MICHALAK M, et al. Identification of serum proteome components associated with progression of non-small cell lung cancer[J]. Acta Biochim Pol, 2014, 61(2): 325-331.
[20] YU HK, KIM JS, LEE HJ, et al. Suppression of colorectal cancer liver metastasis and extension of survival by expression of apolipoprotein(a) kringles[J]. Cancer Res, 2004, 64(19): 7092-7098.
[21] WANG XP, LI XH, ZHANG L, et al. High level of serum apolipoprotein a-I is a favorable prognostic factor for overall survival in esophageal squamous cell carcinoma[J]. BMC Cancer, 2016, 16: 516.
[22] SIRNIO P, VAYRYNEN JP, KLINTRUP K, et al. Decreased serum apolipoprotein A1 levels are associated with poor survival and systemic inflammatory response in colorectal cancer[J]. Sci Rep, 2017, 7(1): 5374.
[23] ZHANG T, WANG Q, WANG Y, et al. Aibp and Apoa-I synergistically inhibit intestinal tumor growth and metastasis by promoting cholesterol efflux[J]. J Transl Med, 2019, 17(1): 161.
[24] GAO F, CHATTOPADHYAY A, NAVAB M, et al. Apolipoprotein A-I mimetic peptides inhibit expression and activity of hypoxia-inducible factor-1α in human ovarian cancer cell lines and a mouse ovarian cancer model[J]. J Pharmacol Exp Ther, 2012, 342(2): 255-262.
[25] CEDO L, GARCIA-LEON A, BAILA-RUEDA L, et al. Apoa-I mimetic administration, but not increased Apoa-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer[J]. Sci Rep, 2016, 6: 36387.
[26] DROST J, CLEVERS H. Organoids in cancer research[J]. Nat Rev Cancer, 2018, 18(7): 407-418.
[27] WEEBER F, OOFT SN, DIJKSTRA KK, et al. Tumor organoids as a pre-clinical cancer model for drug discovery[J]. Cell Chem Biol, 2017, 24(9): 1092-1100.
[28] HAN R, LAI R, DING Q, et al. Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism[J]. Diabetologia, 2007, 50(9): 1960-1968.
[29] VANCURA A, BU P, BHAGWAT M, et al. Metformin as an anticancer agent[J]. Trends Pharmacol Sci, 2018, 39(10): 867-878.